MedTech Founders Advise on Fundraising
On a recent panel, MedTech founders advised that early-stage capital requires strategic angels with deep industry connections over passive checks. One founder noted, "It’s better to have three angels who open doors at Cedars-Sinai... than ten passive checks," emphasizing the need for investors who understand long regulatory timelines.
The emphasis on "strategic angels" reflects a broader trend where investors are concentrating capital into fewer, more mature MedTech companies that show clear clinical validation and regulatory clarity. In 2025, MedTech venture funding hit a three-year high of $16.1 billion, but the total number of deals fell, pushing the median deal value to a record $10.2 million. For early-stage founders, this means non-dilutive funding sources like government grants from the NIH or Department of Defense are crucial for initial capital without sacrificing equity. Programs like the Small Business Innovation Research (SBIR) are specifically designed to foster innovation in public health-critical fields and can be a good option for pre-revenue startups. The long timelines mentioned are no exaggeration; the FDA approval process for a Class III high-risk medical device, known as Premarket Approval (PMA), can take at least 180 days for the FDA's review alone, and this doesn't include the time for clinical trials. For lower-risk devices, the 510(k) pathway, which demonstrates "substantial equivalence" to an existing device, has a 90-day review goal. Los Angeles-based Cedars-Sinai is a key player in this ecosystem, running its own accelerator that provides selected health-tech startups with $100,000 in funding and mentorship from over 300 clinicians and executives. The program targets innovations in AI, digital health, and medical devices, giving founders direct access to a major hospital system. Alumni from the Cedars-Sinai Accelerator include companies tackling issues from early stroke detection (Alva Health) to using virtual reality for pediatric pain management (Paperplane Therapeutics). This highlights the value of investors who can provide more than capital, offering a direct pathway to test, validate, and integrate new technologies in a clinical setting. For USC students, the local ecosystem includes angel groups like the Pasadena Angels and TCA Venture Group, which covers Los Angeles and Southern California. There are also specialized groups such as MedTech Angels, which focuses exclusively on pre-seed, seed, and Series A investments in medical device startups.
